Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bicycle Therapeutics plc - American Depositary Shares (NQ:BCYC)

7.430 -0.010 (-0.13%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bicycle Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 Next >
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Enhances Leadership Team with Key Appointments
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics to Participate in the SVB Securities Global Biopharma Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present End of Dose Escalation Data from Ongoing Phase I/II Study of BT8009 at the 2023 ASCO Genitourinary (GU) Cancers Symposium
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces FDA Fast Track Designation Granted to BT8009 for the Treatment of Adult Patients with Previously Treated Locally Advanced or Metastatic Urothelial Cancer
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present Five Posters Highlighting Preclinical Data from its Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) Programs at the SITC 37th Annual Meeting
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics to Participate in Upcoming Investor Conferences
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article in the Journal of Medicinal Chemistry Highlighting Preclinical Data from BT8009 Program
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT8009 Program in Molecular Cancer Therapeutics
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces BT5528 Phase I Dose Escalation Results in Patients with Advanced Solid Tumors
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article in Bioconjugate Chemistry, Describing an Extension of its Proprietary Technology Platform Based on Bicyclic Peptides
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data from BT7480 Program in the Journal of Medicinal Chemistry
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Further Expansion of Genentech Immuno-Oncology Collaboration
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors Associated with EphA2 Expression
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the Jefferies Healthcare Conference
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics to Present Trials in Progress Poster Featuring BT7480 Phase I/II Clinical Trial at the 2022 ASCO Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Present Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting
From Bicycle Therapeutics
Via Business Wire
Bicycle Therapeutics Announces Updated Preclinical Data on SARS-CoV-2 Antivirals at the 2022 Microbiology Society Annual Meeting
From Bicycle Therapeutics plc
Via Business Wire
Bicycle Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
From Bicycle Therapeutics plc
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.